Posted by Michael Wonder on 24 Jun 2024
argenx announces FDA approval of Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy
21 June 2024 - Third approved indication for Vyvgart and Vyvgart Hytrulo franchise.
argenx today announced that the US FDA has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy.
